Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2

Br J Haematol. 2020 Jul;190(1):e1-e3. doi: 10.1111/bjh.16798. Epub 2020 May 25.
No abstract available

Keywords: COVID-19; Hodgkin lymphoma; SARS-CoV-2; checkpoint inhibitor; haematological malignancy; pembrolizumab.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Anti-Bacterial Agents / administration & dosage*
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Betacoronavirus*
  • Bleomycin / administration & dosage
  • COVID-19
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / drug therapy
  • Cyclophosphamide / administration & dosage
  • Cytarabine / administration & dosage
  • Dacarbazine / administration & dosage
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Hodgkin Disease* / diagnostic imaging
  • Hodgkin Disease* / drug therapy
  • Hodgkin Disease* / virology
  • Humans
  • Hydroxychloroquine / administration & dosage*
  • Idarubicin / administration & dosage
  • Mediastinal Neoplasms* / diagnostic imaging
  • Mediastinal Neoplasms* / drug therapy
  • Mediastinal Neoplasms* / virology
  • Pandemics
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / drug therapy
  • Positron-Emission Tomography*
  • Prednisone / administration & dosage
  • Procarbazine / administration & dosage
  • SARS-CoV-2
  • Treatment Outcome
  • Vinblastine / administration & dosage
  • Vincristine / administration & dosage

Substances

  • Anti-Bacterial Agents
  • Antibodies, Monoclonal, Humanized
  • Cytarabine
  • Bleomycin
  • Procarbazine
  • Hydroxychloroquine
  • Vincristine
  • Vinblastine
  • Etoposide
  • Dacarbazine
  • Doxorubicin
  • Cyclophosphamide
  • pembrolizumab
  • Prednisone
  • Idarubicin

Supplementary concepts

  • ABVD protocol
  • BEACOPP protocol
  • ICE protocol 4